source
- CellCentric secures $220 million Series D to advance oral multiple myeloma drug inobrodibCellCentric, a biotech focused on multiple myeloma, announced a $220 million Series D financing led by Venrock. The capital will fund ongoing Phase 2 trials and a planned Phase 3 study of its oral…
- Color Health expands into cancer treatment coordination with virtual tumor boardsColor Health, a telehealth firm that currently coordinates cancer screening, is moving into providing and coordinating actual cancer care services. CEO Othman Laraki says the growing complexity of…